HomeInsightsStock Comparison

Novartis India Ltd vs Orchid Pharma Ltd Stock Comparison

Novartis India Ltd vs Orchid Pharma Ltd Stock Comparison

Last Updated on: May 02, 2025

Key Highlights

  • The Latest Trading Price of Novartis India Ltd is ₹ 775 as of 02 May 10:57.
  • The P/E Ratio of Novartis India Ltd changed from 0 on March 2020 to 0 on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Orchid Pharma Ltd changed from 33.9 on March 2023 to 57.5 on March 2024 . This represents a CAGR of 30.24% over 2 years.
  • The Market Cap of Novartis India Ltd changed from ₹ 0 crore on March 2020 to ₹ 0 crore on March 2024 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Orchid Pharma Ltd changed from ₹ 10061 crore on March 2021 to ₹ 5301 crore on March 2024 . This represents a CAGR of -14.80% over 4 years.
  • The revenue of Novartis India Ltd for the Dec '24 is ₹ 0 crore as compare to the Sep '24 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Orchid Pharma Ltd for the Dec '24 is ₹ 225.83 crore as compare to the Sep '24 revenue of ₹ 230.22 crore. This represent the decline of -1.91%.
  • The ebitda of Novartis India Ltd for the Dec '24 is ₹ 0 crore as compare to the Sep '24 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Orchid Pharma Ltd for the Dec '24 is ₹ 34.85 crore as compare to the Sep '24 ebitda of ₹ 37.85 crore. This represent the decline of -7.93%.
  • The net profit of Novartis India Ltd changed from ₹ 0 crore to ₹ 0 crore over 7 quarters. This represents a CAGR of 0.0% The net profit of Orchid Pharma Ltd changed from ₹ 10.78 crore to ₹ 22.45 crore over 7 quarters. This represents a CAGR of 52.07% .
  • The Dividend Payout of Novartis India Ltd changed from 244.84 % on March 2020 to 72.43 % on March 2024 . This represents a CAGR of -21.62% over 5 yearsThe Dividend Payout of Orchid Pharma Ltd changed from 0 % on March 2020 to 0 % on March 2024 . This represents a CAGR of 0.0% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Novartis India Ltd

  • Novartis India Limited (NIL) is a subsidiary of Swiss giant Novartis, the world's second largest pharmaceutical company was incorporated on 13 December 1947.
  • The Company is engaged in manufacturing and marketing of drugs, pharmaceutical products and formulations for consumer healthcare and animal healthcare; it operates into four segments such as Pharmaceuticals, Generics, Over the Trade Counter and Animal Health. The origin of Novartis is linked to the origin of three distinct companies namely Geigy, Ciba, and Sandoz.
  • The history of Geigy goes back to the middle of the 18th century, Ciba was founded around 1860, and Sandoz was set-up in 1886.
  • In 1970 Ciba and Geigy merged to form Ciba-Geigy Ltd. Sandoz and Ciba-Geigy Ltd continued as separate entities for the next 25 years.
  • In 1996, in one of the largest corporate mergers in history Sandoz and Ciba-Geigy Ltd.

About Orchid Pharma Ltd

  • Orchid Pharma Limited, is one of the leading pharmaceutical companies in India head quartered in Chennai and involved in development, manufacture and marketing of diverse bulk actives, formulations and nutraceuticals with exports spanning over 40 countries.
  • Orchid's world class manufacturing infrastructure include USFDA compliant API and Finished Dosage Form facilities at Chennai in India.
  • The Company has dedicated state-of-art and GLP compliant R&D infrastructure for Process Research, Drug Discovery and Pharmaceutical Research at Chennai. The Company has a portfolio of antibiotics, and veterinary products.
  • Antibiotics are life-saving drugs used to ght infections.
  • Different classes of antibiotics include Beta-lactam, Macrolide, Fluoroquinolone, Imidazoleetc.

Novartis India Ltd News Hub

News

Novartis India to announce Quarterly Result

Novartis India will hold a meeting of the Board of Directors of the Company on 9 May 2025....

Read more

28 Mar 2025 09:32

News

Novartis India to hold board meeting

Novartis India will hold a meeting of the Board of Directors of the Company on 28 January ...

Read more

28 Dec 2024 09:37

News

Novartis India schedules board meeting

Novartis India will hold a meeting of the Board of Directors of the Company on 25 October ...

Read more

28 Sep 2024 10:07

News

Novartis India to declare Quarterly Result

Novartis India will hold a meeting of the Board of Directors of the Company on 29 July 202...

Read more

28 Jun 2024 17:50

News

Novartis India to conduct AGM

Novartis India announced that the 76th Annual General Meeting(AGM) of the company will be ...

Read more

11 May 2024 11:58

News

Board of Novartis India recommends Final Dividend

Novartis India announced that the Board of Directors of the Company at its meeting held on...

Read more

10 May 2024 17:41

Orchid Pharma Ltd News Hub

News

Orchid Pharma continues to be under rating watch with developing implications

Orchid Pharma announced that CARE has continued the rating CARE A-/ CARE A2 while maintain...

Read more

07 Mar 2025 13:33

News

Orchid Pharma's Alathur facility completes USFDA inspection

Orchid Pharma announced the successful completion of a surprise U.S. Food and Drug Adminis...

Read more

19 Feb 2025 19:36

News

Orchid Pharma to announce Quarterly Result

Orchid Pharma will hold a meeting of the Board of Directors of the Company on 12 February ...

Read more

07 Feb 2025 15:56

News

Orchid Pharma to hold board meeting

Orchid Pharma will hold a meeting of the Board of Directors of the Company on 11 November ...

Read more

06 Nov 2024 12:44

News

Orchid Pharma announces board meeting date

Orchid Pharma will hold a meeting of the Board of Directors of the Company on 12 August 20...

Read more

10 Aug 2024 12:49

News

Orchid Pharma to conduct AGM

Orchid Pharma announced that the Annual General Meeting (AGM) of the company will be held ...

Read more

18 Jul 2024 20:35

SWOT Analysis Of Novartis India Ltd

Strength

1

S

Weakness

0

W

Opportunity

0

O

Threats

0

T

SWOT Analysis Of Orchid Pharma Ltd

Strength

3

S

Weakness

2

W

Opportunity

0

O

Threats

0

T

BlinkX Score for Novartis India Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Orchid Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Novartis India Ltd and Orchid Pharma Ltd

Which company has a larger market capitalization, Novartis India Ltd or Orchid Pharma Ltd?

Market cap of Novartis India Ltd is 1,890 Cr while Market cap of Orchid Pharma Ltd is 4,086 Cr

What are the key factors driving the stock performance of Novartis India Ltd and Orchid Pharma Ltd?

The stock performance of Novartis India Ltd and Orchid Pharma Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Novartis India Ltd and Orchid Pharma Ltd?

As of May 2, 2025, the Novartis India Ltd stock price is INR ₹765.8. On the other hand, Orchid Pharma Ltd stock price is INR ₹805.7.

How do dividend payouts of Novartis India Ltd and Orchid Pharma Ltd compare?

To compare the dividend payouts of Novartis India Ltd and Orchid Pharma Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions